DKK1 (human, recombinant)

Confirm delete?

Zoom

Cat No: 32045

Proteins - More Proteins

Dickkopf-related protein 1 (DKK1) is a glycoprotein and a member of the DKK family of proteins.{56080} DKK1 contains a signal sequence and N- and C-terminal conserved cysteine-rich domains connected by a non-conserved linker region. The C-terminal dom...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

HEK 293 DKK 1 nonconserved LRP 5 6 coreceptor postmortem Thr 32 Ser 35 SDSPAGE SK

Product Overview:
Dickkopf-related protein 1 (DKK1) is a glycoprotein and a member of the DKK family of proteins.{56080} DKK1 contains a signal sequence and N- and C-terminal conserved cysteine-rich domains connected by a non-conserved linker region. The C-terminal domain contains a colipase fold domain that is sufficient for its biological activity. DKK1 is a secretory protein that is expressed in osteoblasts, osteocytes, skin, placenta, prostate, and platelets.{56081} It binds to lipoprotein receptor-related protein 5/6 (LRP5/6) to prevent it from forming a β-catenin-stabilizing complex with Wnt and Frizzled, thus inactivating Wnt-β-catenin signaling. In the presence of the DKK1 co-receptor Kremen, LRP6 is endocytosed to prevent its interaction with Wnt and Frizzled. DKK1 is also a target of the β-catenin-TCF transcription factor complex forming a negative feedback loop for Wnt signaling.{56082} Dkk1 knockout in mice is embryonic lethal with embryos lacking anterior head structures, as well as having ectopic and fused digits and fused vertebrae.{56083} Mice heterozygous for Dkk1 have increased bone density, and overexpression of Dkk1 in mice leads to osteopenia.{56080} DKK1 expression is increased in a variety of cancers and plasma levels are correlated with the development of osteolytic lesion formation in patients with multiple myeloma.{56080,56084} Activation of DKK1 in cancer cells in vitro and in vivo can inhibit growth, however, DKK1 inhibition can reduce tumor growth in certain mouse xenograft models, suggesting a cell- or tissue-specific effect.{56084,56085} DKK1 expression is increased in the brain of Alzheimer’s disease mouse models, cerebrospinal fluid and plasma of patients with Alzheimer’s disease, and in postmortem brain derived from Alzheimer’s disease patients.{56086} Cayman’s DKK1 (human, recombinant) protein can be used for cell-based assay applications. This protein consists of 235 amino acids, has a calculated molecular weight of 25.8 kDa, and a predicted N-terminus of Thr32 or Ser35 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is approximately 45 kDa due to glycosylation.

Size	20 µg
Shipping	dry ice
Formulation	Lyophilized from sterile PBS, pH 7.4
Purity	≥90% estimated by SDS-PAGE
Custom Code	3504.00
UNSPSC code	12352204

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.